Femasys (FEMY) Competitors $0.88 -0.06 (-6.06%) Closing price 04:00 PM EasternExtended Trading$0.90 +0.02 (+2.27%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. SLNO, MBOT, APYX, GUTS, TELA, SRTS, VANI, ZYXI, NVNO, and NSPRShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Soleno Therapeutics (SLNO), Microbot Medical (MBOT), Apyx Medical (APYX), Fractyl Health (GUTS), TELA Bio (TELA), Sensus Healthcare (SRTS), Vivani Medical (VANI), Zynex (ZYXI), enVVeno Medical (NVNO), and InspireMD (NSPR). These companies are all part of the "medical equipment" industry. Femasys vs. Its Competitors Soleno Therapeutics Microbot Medical Apyx Medical Fractyl Health TELA Bio Sensus Healthcare Vivani Medical Zynex enVVeno Medical InspireMD Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Do insiders & institutionals hold more shares of FEMY or SLNO? 65.3% of Femasys shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 11.5% of Femasys shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer FEMY or SLNO? In the previous week, Soleno Therapeutics had 8 more articles in the media than Femasys. MarketBeat recorded 9 mentions for Soleno Therapeutics and 1 mentions for Femasys. Soleno Therapeutics' average media sentiment score of 0.94 beat Femasys' score of 0.93 indicating that Soleno Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is FEMY or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,242.06%. Soleno Therapeutics' return on equity of -77.52% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,242.06% -392.45% -137.15% Soleno Therapeutics N/A -77.52%-63.44% Which has stronger earnings and valuation, FEMY or SLNO? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.63M17.56-$18.82M-$0.91-0.97Soleno TherapeuticsN/AN/A-$175.85M-$4.62-18.87 Which has more volatility and risk, FEMY or SLNO? Femasys has a beta of -2.56, indicating that its stock price is 356% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.63, indicating that its stock price is 363% less volatile than the S&P 500. Do analysts recommend FEMY or SLNO? Femasys presently has a consensus target price of $8.67, suggesting a potential upside of 884.85%. Soleno Therapeutics has a consensus target price of $108.70, suggesting a potential upside of 24.66%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 SummarySoleno Therapeutics beats Femasys on 9 of the 16 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.47M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-0.978.2821.0120.09Price / Sales17.56303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book8.807.678.125.65Net Income-$18.82M-$55.28M$3.25B$257.91M7 Day Performance-4.84%2.50%0.97%2.09%1 Month PerformanceN/A11.70%7.36%11.13%1 Year Performance-20.72%4.89%31.31%18.40% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys2.9033 of 5 stars$0.88-6.1%$8.67+884.8%-18.5%$30.47M$1.63M-0.9730SLNOSoleno Therapeutics4.1852 of 5 stars$85.27-1.6%$107.10+25.6%+80.0%$4.37BN/A-18.4630Analyst RevisionMBOTMicrobot Medical2.3037 of 5 stars$2.51-3.5%$9.00+258.6%+135.5%$94.58MN/A-3.8620APYXApyx Medical2.2374 of 5 stars$2.58+12.7%N/A+65.2%$86.55M$48.10M-4.69270High Trading VolumeGUTSFractyl Health2.2442 of 5 stars$1.54-6.7%$11.00+614.3%-62.1%$80.81M$90K-0.83102TELATELA Bio2.9991 of 5 stars$1.93-5.4%$7.25+275.6%-57.2%$80.69M$69.30M-1.37120Positive NewsGap UpSRTSSensus Healthcare1.0757 of 5 stars$4.59-1.5%$11.67+154.2%-23.4%$76.63M$41.81M45.9040News CoverageVANIVivani Medical3.1812 of 5 stars$1.27+0.8%$4.00+215.0%+19.5%$74.65MN/A-2.9520ZYXIZynex2.044 of 5 stars$2.51+4.6%$6.00+139.0%-77.2%$72.57M$192.35M-10.46770Upcoming EarningsAnalyst ForecastNVNOenVVeno Medical0.5079 of 5 stars$3.93-1.5%N/A-11.8%$69.97MN/A-3.3330NSPRInspireMD2.9086 of 5 stars$2.22-0.9%$4.50+102.7%-0.8%$68.62M$7.03M-2.9650High Trading Volume Related Companies and Tools Related Companies Soleno Therapeutics Alternatives Microbot Medical Alternatives Apyx Medical Alternatives Fractyl Health Alternatives TELA Bio Alternatives Sensus Healthcare Alternatives Vivani Medical Alternatives Zynex Alternatives enVVeno Medical Alternatives InspireMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FEMY Stock Alerts